46例无创正压治疗COPD急性加重期伴呼吸衰竭临床分析

Metoprolol for chronic congestive heart failure： a clinical analysis of 46 cases

目的探讨无创正压治疗COPD急性加重期伴呼衰的临床疗效。方法选择2007年1月-2009年12月收治于我院的COPD急性加重期伴呼衰患者92例，随机分为观察组（46例）和对照组（46例），对照组采用常规疗法治疗；治疗组在常规治疗的基础上加用无创正压通气治疗，比较两组治疗效果。结果观察组在治疗后PaCO2（42．24±6．22）mmHg、呼吸频率（21．2±1．3）次／分、PaO2（89．26±9．27）mmHg，治疗效果显著优于对照组（P〈0．05）。结论无创正压通气治疗COPD急性加重期伴呼衰患者，能有效的降低PaCO2、呼吸频率和提高PaO2等，具有较好的临床疗效。

Objective To explore the efficay of metoprolol for chronic congestive heart failure. Methods 92 patients with chronic congestive heart failure admitted during the period of January 2008 to December 2009 were randomly assigned to receive combination therapy with cardiac glycosides, diuretics, and ACE inhibitors （control group） or the combination therapy plus metoprolol （study group）. The efficacy was compared between the two groups. Results 6 months after treatment, the study group was superior to the control group in efficacy （91.3% vs. 76.1% for total effective rate, P〈0.05）. Conclusions Metoprolol for chronic congestive heart failure can improve LVEF, LVDd, and LVPWT, resulting in a better clinical efficacy.